Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study

Journal of Pharmaceutical Policy and Practice

Vikky Entwistle¹  Tuan Nguyen¹  Elizabeth Roughead¹  Agnes Vitry¹ 

[1] Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001 Australia

关键词: Pharmaceutical policy;    Managed entry agreement;    Medicine subsidization;    Coverage with evidence development;   

DOI  :  10.1186/s40545-015-0046-2

学科分类：药理学

来源: BioMed Central

【 摘 要 】

Background

Withdrawal of conditional regulatory approval or subsidization of new medicines when subsequent evidence does not confirm early trial results may not be well understood or accepted by the public.

【 授权许可】

Unknown